A new trading day began on Monday, with ARS Pharmaceuticals Inc (NASDAQ: SPRY) stock price down -8.20% from the previous day of trading, before settling in for the closing price of $14.51. SPRY’s price has ranged from $4.76 to $18.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -34.76%. Meanwhile, its annual earnings per share averaged 12.72%. With a float of $50.84 million, this company’s outstanding shares have now reached $97.15 million.
Let’s determine the extent of company efficiency that accounts for 26 employees. In terms of profitability, gross margin is 93.97%, operating margin of -2384.0%, and the pretax margin is -1934.75%.
ARS Pharmaceuticals Inc (SPRY) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of ARS Pharmaceuticals Inc is 47.79%, while institutional ownership is 42.07%. The most recent insider transaction that took place on Dec 02 ’24, was worth 652,950. Before that another transaction happened on Dec 02 ’24, when Company’s Director proposed sale 200,000 for $13.56, making the entire transaction worth $2,713,000.
ARS Pharmaceuticals Inc (SPRY) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.07 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.72% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Here are ARS Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 503.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Looking closely at ARS Pharmaceuticals Inc (NASDAQ: SPRY), its last 5-days average volume was 0.85 million, which is a jump from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 58.73%. Additionally, its Average True Range was 0.98.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 45.96%, which indicates a significant increase from 6.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.36% in the past 14 days, which was higher than the 72.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.79, while its 200-day Moving Average is $11.14. However, in the short run, ARS Pharmaceuticals Inc’s stock first resistance to watch stands at $14.06. Second resistance stands at $14.79. The third major resistance level sits at $15.19. If the price goes on to break the first support level at $12.92, it is likely to go to the next support level at $12.52. Should the price break the second support level, the third support level stands at $11.79.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
With a market capitalization of 1.29 billion, the company has a total of 97,185K Shares Outstanding. Currently, annual sales are 30 K while annual income is -54,370 K. The company’s previous quarter sales were 2,070 K while its latest quarter income was -19,130 K.
